Key result
ACT-based heparin dose-response testing poorly predicts required intraprocedural heparin dosing due to nonlinear response.
Why the study?
No guidelines currently exist for intraprocedural anticoagulant administration and monitoring in dogs, despite the prevalence of procedures requiring systemic heparin anticoagulation.
Does an ACT-based heparin dose-response test accurately predict the optimal heparin dose in dogs during intravascular procedures?
Does an ACT-based heparin dose-response test accurately predict the optimal heparin dose in dogs during intravascular procedures?
An ACT-based heparin dose-response test poorly estimates the required intravenous heparin dose in dogs due to a highly variable and nonlinear heparin-ACT response, suggesting anti-Xa may be a more reliable alternative if practical limitations can be overcome.
Answers are grounded in this paper and cite their sources.
ACT-based heparin dosing may overestimate needs in dogs; leaves open anti-Xa validation for veterinary procedures.
BACKGROUND: No guidelines for administering and monitoring anticoagulants intraprocedurally are currently available in dogs, despite the prevalence of procedures necessitating systemic anticoagulation with heparin. OBJECTIVES: To evaluate an activated clotting time (ACT)-based heparin dose-response (HDR) test to predict the individual required heparin dose in dogs during intravascular procedures, and to investigate both the in vitro heparin - ACT and in vitro heparin - factor anti-Xa activity (anti-Xa) relationships in dogs. METHODS: Blood was collected from eight healthy beagles undergoing a cardiac procedure and utilised to establish baseline ACT and for in vitro evaluation. Subsequently, 100 IU/kg heparin was administered intravenously (IV) and ACT was remeasured (HDR test). The required heparin dose for an ACT target response ≥300 s was calculated for each individual and ACT was remeasured after administration of this dose. For in vitro testing, a serial heparin blood dilution (0-0.5-1-2-4 international unit (IU)/mL) was prepared and ACT and anti-Xa were determined using whole blood and frozen plasma, respectively. RESULTS: The HDR test overestimated the required heparin dose in 3/7 dogs. In vitro, ACT and anti-Xa increased significantly with increasing blood heparin concentration. Heparin - ACT was nonlinear in 4/8 dogs at heparin concentrations >2 IU/mL, whereas heparin - anti-Xa remained linear throughout the tested range. CONCLUSIONS: The HDR test poorly estimated the required heparin dose in dogs. This is most likely attributed to a nonlinear heparin - ACT relationship, as observed in vitro. Anti-Xa is a promising alternative for ACT; however, unavailability as a point-of-care test and lack of in vivo target values restrict its current use.
No takes yet. Share an insight, caveat, or question.
Hellemans et al. (2023) studied Healthy dogs requiring intraprocedural heparinization (n=8). Activated clotting time (ACT)-based heparin dose-response (HDR) test was evaluated on Predictive value of the HDR test for required heparin dose to achieve target ACT ≥300 s. An activated clotting time-based heparin dose-response test poorly estimated the required intraprocedural heparin dose in dogs, likely due to a nonlinear heparin-ACT relationship observed at higher concentrations.
Synapse has enriched 10 related papers. Consider them for comparative context: